Business
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
ALISO VIEJO, Calif., January 28, 2026--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an NDA labeling supplement allowing for re-administration of iDose® TR using a repeat treatment protocol. The FDA approval is in response to Glaukos’ 2025 NDA labeling supplement application, and re
About this update from Glaukos Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2774,"height":518,"url":"https://media.zenfs.com/en/business-wire.com/e41099da6c6bc115c43ba63d22dc7627"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D0gxX1KwsD29MRoFhNsP9w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e41099da6c6bc115c43ba63d22dc7627","width":960,"height":179},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/KhcxPbrANSk6O1IQg05Mbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e41099da6c6bc115c43ba63d22dc7627","width":1200,"height":224}},"lazy":false},{"type":"text","content":"ALISO VIEJO, Calif., January 28, 2026--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an NDA labeling supplement allowing for re-administration of iDose® TR using a repeat treatment protocol. The FDA approval is in response to Glaukos’ 2025 NDA labeling supplement application, and reflects accumulated clinical evidence supporting the safety and tolerability of repeat use for iDose TR.","length":620,"tagName":"p"},{"type":"text","content":""We are pleased to announce this important labeling enhancement for iDose TR, which should help expand access for patients who may benefit from repeat treatment and provide physicians with greater flexibility in managing their glaucoma patients over time," said Thomas Burns, Glaukos chairman and chief executive officer. "This approval further validates iDose TR’s established and proven safety profile and reinforces its leading position in addressing the strong and growing demand within the ophthalmic community for safe, effective, and sustained procedural pharmaceutical alternatives to traditional topical medications."","length":646,"tagName":"p"},{"type":"text","content":"Under the updated labeling, physicians may now re-administer iDose TR more than once in patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters. In clinical studies, iDose TR has demonstrated a favorable lo...